Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Erratum to: Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen.

Thorsted A, Kristoffersson AN, Maarbjerg SF, Schrøder H, Wang M, Brock B, Nielsen EI, Friberg LE.

J Antimicrob Chemother. 2019 Oct 25. pii: dkz429. doi: 10.1093/jac/dkz429. [Epub ahead of print] No abstract available.

PMID:
31650174
2.

Population pharmacokinetics of piperacillin in febrile children receiving cancer chemotherapy: the impact of body weight and target on an optimal dosing regimen.

Thorsted A, Kristoffersson AN, Maarbjerg SF, Schrøder H, Wang M, Brock B, Nielsen EI, Friberg LE.

J Antimicrob Chemother. 2019 Oct 1;74(10):2984-2993. doi: 10.1093/jac/dkz270.

PMID:
31273375
3.

Effects of cladribine tablets on heart rate, atrio-ventricular conduction and cardiac repolarization in patients with relapsing multiple sclerosis.

Hermann R, Litwin JS, Friberg LE, Dangond F, Munafo A.

Br J Clin Pharmacol. 2019 Jul;85(7):1484-1494. doi: 10.1111/bcp.13919. Epub 2019 May 6.

4.

A non-linear mixed effect model for innate immune response: In vivo kinetics of endotoxin and its induction of the cytokines tumor necrosis factor alpha and interleukin-6.

Thorsted A, Bouchene S, Tano E, Castegren M, Lipcsey M, Sjölin J, Karlsson MO, Friberg LE, Nielsen EI.

PLoS One. 2019 Feb 21;14(2):e0211981. doi: 10.1371/journal.pone.0211981. eCollection 2019.

5.

Piperacillin pharmacokinetics and target attainment in children with cancer and fever: Can we optimize our dosing strategy?

Maarbjerg SF, Thorsted A, Kristoffersson A, Friberg LE, Nielsen EI, Wang M, Brock B, Schrøder H.

Pediatr Blood Cancer. 2019 Jun;66(6):e27654. doi: 10.1002/pbc.27654. Epub 2019 Feb 10.

PMID:
30740885
6.

Association between Paclitaxel Clearance and Tumor Response in Patients with Esophageal Cancer.

Toxopeus ELA, de Man FM, Krak N, Biermann K, Nieuweboer AJM, Friberg LE, Oomen-de Hoop E, van Lanschot JJB, Shapiro J, Wijnhoven BPL, Mathijssen RHJ.

Cancers (Basel). 2019 Feb 1;11(2). pii: E173. doi: 10.3390/cancers11020173.

7.

Treatment Outcomes of Colistin- and Carbapenem-resistant Acinetobacter baumannii Infections: An Exploratory Subgroup Analysis of a Randomized Clinical Trial.

Dickstein Y, Lellouche J, Ben Dalak Amar M, Schwartz D, Nutman A, Daitch V, Yahav D, Leibovici L, Skiada A, Antoniadou A, Daikos GL, Andini R, Zampino R, Durante-Mangoni E, Mouton JW, Friberg LE, Dishon Benattar Y, Bitterman R, Neuberger A, Carmeli Y, Paul M; AIDA Study Group .

Clin Infect Dis. 2019 Aug 16;69(5):769-776. doi: 10.1093/cid/ciy988.

PMID:
30462182
8.

Model-Based Drug Development in Pulmonary Delivery: Pharmacokinetic Analysis of Novel Drug Candidates for Treatment of Pseudomonas aeruginosa Lung Infection.

Sou T, Kukavica-Ibrulj I, Soukarieh F, Halliday N, Levesque RC, Williams P, Stocks M, Cámara M, Friberg LE, Bergström CAS.

J Pharm Sci. 2019 Jan;108(1):630-640. doi: 10.1016/j.xphs.2018.09.017. Epub 2018 Sep 23.

9.

A PK/PD Analysis of Circulating Biomarkers and Their Relationship to Tumor Response in Atezolizumab-Treated non-small Cell Lung Cancer Patients.

Netterberg I, Li CC, Molinero L, Budha N, Sukumaran S, Stroh M, Jonsson EN, Friberg LE.

Clin Pharmacol Ther. 2019 Feb;105(2):486-495. doi: 10.1002/cpt.1198. Epub 2018 Sep 4.

10.

A Pharmacometric Analysis of Patient-Reported Outcomes in Breast Cancer Patients Through Item Response Theory.

Schindler E, Friberg LE, Lum BL, Wang B, Quartino A, Li C, Girish S, Jin JY, Karlsson MO.

Pharm Res. 2018 Apr 19;35(6):122. doi: 10.1007/s11095-018-2403-8.

11.

A Whole-Body Physiologically Based Pharmacokinetic Model for Colistin and Colistin Methanesulfonate in Rat.

Bouchene S, Marchand S, Couet W, Friberg LE, Gobin P, Lamarche I, Grégoire N, Björkman S, Karlsson MO.

Basic Clin Pharmacol Toxicol. 2018 Oct;123(4):407-422. doi: 10.1111/bcpt.13026. Epub 2018 Jun 8.

12.

Correction to: Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology.

Pierrillas PB, Fouliard S, Chenel M, Hooker AC, Friberg LE, Karlsson MO.

AAPS J. 2018 Mar 27;20(3):55. doi: 10.1208/s12248-018-0218-5.

PMID:
29589158
13.

Reply to Prim et al., "Is Colistin Susceptibility Testing Finally on the Right Track?"

Karvanen M, Malmberg C, Lagerbäck P, Friberg LE, Cars O.

Antimicrob Agents Chemother. 2018 Mar 27;62(4). pii: e02507-17. doi: 10.1128/AAC.02507-17. Print 2018 Apr. No abstract available.

14.

Population Pharmacokinetics of Meropenem in Plasma and Subcutis from Patients on Extracorporeal Membrane Oxygenation Treatment.

Hanberg P, Öbrink-Hansen K, Thorsted A, Bue M, Tøttrup M, Friberg LE, Hardlei TF, Søballe K, Gjedsted J.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02390-17. doi: 10.1128/AAC.02390-17. Print 2018 May.

15.

Model-Based Adaptive Optimal Design (MBAOD) Improves Combination Dose Finding Designs: an Example in Oncology.

Pierrillas PB, Fouliard S, Chenel M, Hooker AC, Friberg LE, Karlsson MO.

AAPS J. 2018 Mar 7;20(2):39. doi: 10.1208/s12248-018-0206-9. Erratum in: AAPS J. 2018 Mar 27;20(3):55.

PMID:
29516207
16.

Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered?

Andersen MG, Thorsted A, Storgaard M, Kristoffersson AN, Friberg LE, Öbrink-Hansen K.

Antimicrob Agents Chemother. 2018 Apr 26;62(5). pii: e02306-17. doi: 10.1128/AAC.02306-17. Print 2018 May.

17.

Colistin alone versus colistin plus meropenem for treatment of severe infections caused by carbapenem-resistant Gram-negative bacteria: an open-label, randomised controlled trial.

Paul M, Daikos GL, Durante-Mangoni E, Yahav D, Carmeli Y, Benattar YD, Skiada A, Andini R, Eliakim-Raz N, Nutman A, Zusman O, Antoniadou A, Pafundi PC, Adler A, Dickstein Y, Pavleas I, Zampino R, Daitch V, Bitterman R, Zayyad H, Koppel F, Levi I, Babich T, Friberg LE, Mouton JW, Theuretzbacher U, Leibovici L.

Lancet Infect Dis. 2018 Apr;18(4):391-400. doi: 10.1016/S1473-3099(18)30099-9. Epub 2018 Feb 16.

PMID:
29456043
18.

Semi-mechanistic pharmacokinetic-pharmacodynamic modelling of antibiotic drug combinations.

Brill MJE, Kristoffersson AN, Zhao C, Nielsen EI, Friberg LE.

Clin Microbiol Infect. 2018 Jul;24(7):697-706. doi: 10.1016/j.cmi.2017.11.023. Epub 2017 Dec 8. Review.

19.

The risk of febrile neutropenia in breast cancer patients following adjuvant chemotherapy is predicted by the time course of interleukin-6 and C-reactive protein by modelling.

Netterberg I, Karlsson MO, Nielsen EI, Quartino AL, Lindman H, Friberg LE.

Br J Clin Pharmacol. 2018 Mar;84(3):490-500. doi: 10.1111/bcp.13477. Epub 2018 Jan 18.

20.

Predicting mutant selection in competition experiments with ciprofloxacin-exposed Escherichia coli.

Khan DD, Lagerbäck P, Malmberg C, Kristoffersson AN, Wistrand-Yuen E, Sha C, Cars O, Andersson DI, Hughes D, Nielsen EI, Friberg LE.

Int J Antimicrob Agents. 2018 Mar;51(3):399-406. doi: 10.1016/j.ijantimicag.2017.10.019. Epub 2017 Nov 7.

PMID:
29127049
21.

Can a pharmacokinetic/pharmacodynamic (PKPD) model be predictive across bacterial densities and strains? External evaluation of a PKPD model describing longitudinal in vitro data.

Nielsen EI, Khan DD, Cao S, Lustig U, Hughes D, Andersson DI, Friberg LE.

J Antimicrob Chemother. 2017 Nov 1;72(11):3108-3116. doi: 10.1093/jac/dkx269.

PMID:
28961946
22.

Colistin Is Extensively Lost during Standard In Vitro Experimental Conditions.

Karvanen M, Malmberg C, Lagerbäck P, Friberg LE, Cars O.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e00857-17. doi: 10.1128/AAC.00857-17. Print 2017 Nov.

23.

Advanced Methods for Dose and Regimen Finding During Drug Development: Summary of the EMA/EFPIA Workshop on Dose Finding (London 4-5 December 2014).

Musuamba FT, Manolis E, Holford N, Cheung S, Friberg LE, Ogungbenro K, Posch M, Yates J, Berry S, Thomas N, Corriol-Rohou S, Bornkamp B, Bretz F, Hooker AC, Van der Graaf PH, Standing JF, Hay J, Cole S, Gigante V, Karlsson K, Dumortier T, Benda N, Serone F, Das S, Brochot A, Ehmann F, Hemmings R, Rusten IS.

CPT Pharmacometrics Syst Pharmacol. 2017 Jul;6(7):418-429. doi: 10.1002/psp4.12196. Epub 2017 Jul 19.

24.

Model-based prediction of myelosuppression and recovery based on frequent neutrophil monitoring.

Netterberg I, Nielsen EI, Friberg LE, Karlsson MO.

Cancer Chemother Pharmacol. 2017 Aug;80(2):343-353. doi: 10.1007/s00280-017-3366-x. Epub 2017 Jun 27.

25.

Item Response Theory to Quantify Longitudinal Placebo and Paliperidone Effects on PANSS Scores in Schizophrenia.

Krekels E, Novakovic AM, Vermeulen AM, Friberg LE, Karlsson MO.

CPT Pharmacometrics Syst Pharmacol. 2017 Aug;6(8):543-551. doi: 10.1002/psp4.12207. Epub 2017 Jul 13.

26.

Population Pharmacokinetic Modeling as a Tool To Characterize the Decrease in Ciprofloxacin Free Interstitial Levels Caused by Pseudomonas aeruginosa Biofilm Lung Infection in Wistar Rats.

Torres BGS, Helfer VE, Bernardes PM, Macedo AJ, Nielsen EI, Friberg LE, Dalla Costa T.

Antimicrob Agents Chemother. 2017 Jun 27;61(7). pii: e02553-16. doi: 10.1128/AAC.02553-16. Print 2017 Jul.

27.

The role of infection models and PK/PD modelling for optimising care of critically ill patients with severe infections.

Tängdén T, Ramos Martín V, Felton TW, Nielsen EI, Marchand S, Brüggemann RJ, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA; Infection Section for the European Society of Intensive Care Medicine, the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases, the International Society of Anti-Infective Pharmacology and the Critically Ill Patients Study Group of European Society of Clinical Microbiology and Infectious Diseases.

Intensive Care Med. 2017 Jul;43(7):1021-1032. doi: 10.1007/s00134-017-4780-6. Epub 2017 Apr 13. Review.

PMID:
28409203
28.

Pharmacometric Modeling of Liver Metastases' Diameter, Volume, and Density and Their Relation to Clinical Outcome in Imatinib-Treated Patients With Gastrointestinal Stromal Tumors.

Schindler E, Krishnan SM, Mathijssen R, Ruggiero A, Schiavon G, Friberg LE.

CPT Pharmacometrics Syst Pharmacol. 2017 Jul;6(7):449-457. doi: 10.1002/psp4.12195. Epub 2017 May 30.

29.

A Pharmacometric Framework for Axitinib Exposure, Efficacy, and Safety in Metastatic Renal Cell Carcinoma Patients.

Schindler E, Amantea MA, Karlsson MO, Friberg LE.

CPT Pharmacometrics Syst Pharmacol. 2017 Jun;6(6):373-382. doi: 10.1002/psp4.12193. Epub 2017 May 26.

30.

Assessment of early combination effects of colistin and meropenem against Pseudomonas aeruginosa and Acinetobacter baumannii in dynamic time-kill experiments.

Tängdén T, Karvanen M, Friberg LE, Odenholt I, Cars O.

Infect Dis (Lond). 2017 Jul;49(7):521-527. doi: 10.1080/23744235.2017.1296183. Epub 2017 Mar 6.

PMID:
28264618
31.

A whole-body physiologically based pharmacokinetic (WB-PBPK) model of ciprofloxacin: a step towards predicting bacterial killing at sites of infection.

Sadiq MW, Nielsen EI, Khachman D, Conil JM, Georges B, Houin G, Laffont CM, Karlsson MO, Friberg LE.

J Pharmacokinet Pharmacodyn. 2017 Apr;44(2):69-79. doi: 10.1007/s10928-016-9486-9. Epub 2016 Aug 30.

32.

Challenge for higher colistin dosage in critically ill patients receiving continuous venovenous haemodiafiltration.

Karaiskos I, Friberg LE, Galani L, Ioannidis K, Katsouda E, Athanassa Z, Paskalis H, Giamarellou H.

Int J Antimicrob Agents. 2016 Sep;48(3):337-41. doi: 10.1016/j.ijantimicag.2016.06.008. Epub 2016 Jul 18.

PMID:
27474468
33.

PK-PD modeling of individual lesion FDG-PET response to predict overall survival in patients with sunitinib-treated gastrointestinal stromal tumor.

Schindler E, Amantea MA, Karlsson MO, Friberg LE.

CPT Pharmacometrics Syst Pharmacol. 2016 Apr;5(4):173-81. doi: 10.1002/psp4.12057. Epub 2016 Mar 16.

34.

Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer.

Zecchin C, Gueorguieva I, Enas NH, Friberg LE.

Br J Clin Pharmacol. 2016 Sep;82(3):717-27. doi: 10.1111/bcp.12994. Epub 2016 Jun 8.

35.

Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol.

Dickstein Y, Leibovici L, Yahav D, Eliakim-Raz N, Daikos GL, Skiada A, Antoniadou A, Carmeli Y, Nutman A, Levi I, Adler A, Durante-Mangoni E, Andini R, Cavezza G, Mouton JW, Wijma RA, Theuretzbacher U, Friberg LE, Kristoffersson AN, Zusman O, Koppel F, Dishon Benattar Y, Altunin S, Paul M; AIDA consortium.

BMJ Open. 2016 Apr 20;6(4):e009956. doi: 10.1136/bmjopen-2015-009956.

36.

A pharmacokinetic-pharmacodynamic (PKPD) model based on in vitro time-kill data predicts the in vivo PK/PD index of colistin.

Khan DD, Friberg LE, Nielsen EI.

J Antimicrob Chemother. 2016 Jul;71(7):1881-4. doi: 10.1093/jac/dkw057. Epub 2016 Mar 16.

PMID:
26983860
37.

Dynamic interaction of colistin and meropenem on a WT and a resistant strain of Pseudomonas aeruginosa as quantified in a PK/PD model.

Mohamed AF, Kristoffersson AN, Karvanen M, Nielsen EI, Cars O, Friberg LE.

J Antimicrob Chemother. 2016 May;71(5):1279-90. doi: 10.1093/jac/dkv488. Epub 2016 Feb 4.

PMID:
26850719
38.

Simulation-Based Evaluation of PK/PD Indices for Meropenem Across Patient Groups and Experimental Designs.

Kristoffersson AN, David-Pierson P, Parrott NJ, Kuhlmann O, Lave T, Friberg LE, Nielsen EI.

Pharm Res. 2016 May;33(5):1115-25. doi: 10.1007/s11095-016-1856-x. Epub 2016 Jan 19.

PMID:
26786016
39.

Inter occasion variability in individual optimal design.

Kristoffersson AN, Friberg LE, Nyberg J.

J Pharmacokinet Pharmacodyn. 2015 Dec;42(6):735-50. doi: 10.1007/s10928-015-9449-6. Epub 2015 Oct 1.

40.

Colistin Population Pharmacokinetics after Application of a Loading Dose of 9 MU Colistin Methanesulfonate in Critically Ill Patients.

Karaiskos I, Friberg LE, Pontikis K, Ioannidis K, Tsagkari V, Galani L, Kostakou E, Baziaka F, Paskalis C, Koutsoukou A, Giamarellou H.

Antimicrob Agents Chemother. 2015 Dec;59(12):7240-8. doi: 10.1128/AAC.00554-15. Epub 2015 Sep 14.

41.

A mechanism-based pharmacokinetic/pharmacodynamic model allows prediction of antibiotic killing from MIC values for WT and mutants.

Khan DD, Lagerbäck P, Cao S, Lustig U, Nielsen EI, Cars O, Hughes D, Andersson DI, Friberg LE.

J Antimicrob Chemother. 2015 Nov;70(11):3051-60. doi: 10.1093/jac/dkv233. Epub 2015 Sep 7.

PMID:
26349518
42.

A pharmacokinetic binding model for bevacizumab and VEGF165 in colorectal cancer patients.

Panoilia E, Schindler E, Samantas E, Aravantinos G, Kalofonos HP, Christodoulou C, Patrinos GP, Friberg LE, Sivolapenko G.

Cancer Chemother Pharmacol. 2015 Apr;75(4):791-803. doi: 10.1007/s00280-015-2701-3. Epub 2015 Feb 17.

43.

Optimizing oncology therapeutics through quantitative translational and clinical pharmacology: challenges and opportunities.

Venkatakrishnan K, Friberg LE, Ouellet D, Mettetal JT, Stein A, Trocóniz IF, Bruno R, Mehrotra N, Gobburu J, Mould DR.

Clin Pharmacol Ther. 2015 Jan;97(1):37-54. doi: 10.1002/cpt.7. Epub 2014 Dec 9. Review.

PMID:
25670382
44.

Performance of nonlinear mixed effects models in the presence of informative dropout.

Björnsson MA, Friberg LE, Simonsson US.

AAPS J. 2015 Jan;17(1):245-55. doi: 10.1208/s12248-014-9700-x. Epub 2014 Nov 25.

45.

Simultaneous Exposure-Response Modeling of ACR20, ACR50, and ACR70 Improvement Scores in Rheumatoid Arthritis Patients Treated With Certolizumab Pegol.

Lacroix BD, Karlsson MO, Friberg LE.

CPT Pharmacometrics Syst Pharmacol. 2014 Oct 29;3:e143. doi: 10.1038/psp.2014.41.

46.

Characterization of endogenous G-CSF and the inverse correlation to chemotherapy-induced neutropenia in patients with breast cancer using population modeling.

Quartino AL, Karlsson MO, Lindman H, Friberg LE.

Pharm Res. 2014 Dec;31(12):3390-403. doi: 10.1007/s11095-014-1429-9. Epub 2014 Jun 12.

PMID:
24919931
47.

A mechanistic pharmacokinetic model elucidating the disposition of trastuzumab emtansine (T-DM1), an antibody-drug conjugate (ADC) for treatment of metastatic breast cancer.

Bender B, Leipold DD, Xu K, Shen BQ, Tibbitts J, Friberg LE.

AAPS J. 2014 Sep;16(5):994-1008. doi: 10.1208/s12248-014-9618-3. Epub 2014 Jun 11.

48.

A review of mixed-effects models of tumor growth and effects of anticancer drug treatment used in population analysis.

Ribba B, Holford NH, Magni P, Trocóniz I, Gueorguieva I, Girard P, Sarr C, Elishmereni M, Kloft C, Friberg LE.

CPT Pharmacometrics Syst Pharmacol. 2014 May 7;3:e113. doi: 10.1038/psp.2014.12.

49.

CPT: Pharmacometrics & Systems Pharmacology Publishes Its 100th Article.

van der Graaf PH, Friberg LE.

CPT Pharmacometrics Syst Pharmacol. 2014 Mar 5;3:e104. doi: 10.1038/psp.2014.4. No abstract available.

50.

Supplemental Content

Loading ...
Support Center